SUMSearch 2

Original studies

Systematic reviews

Guidelines

 
50 found after 3 searches:
1. Drug-coated balloon for treatment of non-atherosclerotic renal artery stenosis-a multi-center study.
BMC Cardiovasc Disord 2023;23:1. PMID: 37845604 , PubMed Central, doi: 10.1186/s12872-023-03484-5, Cited by. Cite
Conclusion: Protocol version V.4 (3 May 2023).
2. Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
Cardiovasc Intervent Radiol 2021;44:2. PMID: 33025243 , PubMed Central, doi: 10.1007/s00270-020-02648-6, Cited by. Cite
Conclusion: This is the first prediction model that uses an extensive dataset to determine the impact of patient and lesion factors on ffTLR through 5 years and provides an interactive web-based tool for expected patient outcomes with the Zilver PTX DES.
3. Clinical predictors of blood pressure response after renal artery stenting.
J Vasc Surg 2020;72:4. PMID: 32139312 , doi: 10.1016/j.jvs.2019.12.041, Cited by. Cite
Conclusion: trial who underwent RAS, the previously reported clinical markers of BP response were validated. A prospective trial to validate their utility as predictors of BP response to RAS is warranted.
Impact/quality: Accompanied by editorial; *
4. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
Lancet 2019;394:10204. PMID: 31484629 , doi: 10.1016/S0140-6736(19)31887-2, Cited by. Cite
Conclusion: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk.
Impact/quality: Accompanied by editorial; * Review (at http://www.acpjc.org/); **
5. Early Rapid Decline in Kidney Function in Medically Managed Patients With Atherosclerotic Renal Artery Stenosis.
J Am Heart Assoc 2019;8:11. PMID: 31433717 , PubMed Central, doi: 10.1161/JAHA.119.012366, Cited by. Cite
Conclusion: The regression to the mean of improvement in eGFR at 1 year in the RD group was estimated at 5.8±7.1%. Conclusions Early rapid declines in kidney function may occur in patients with renal artery stenosis when medical therapy is initiated, and their clinical outcomes are comparable to those without such a decline, when medical therapy only is continued.
Impact/quality: Accompanied by editorial; * Governmental/foundation support *
6. A randomized unblinded trial to compare effects of intensive versus conventional lipid-lowering therapy in patients undergoing renal artery stenting.
J Cardiol 2019;74:5. PMID: 31235418 , doi: 10.1016/j.jjcc.2019.04.010, Cited by. Cite
Conclusion: In patients with severe ARAS undergoing stent placement, intensive lipid lowering showed significant benefits in renal protection over conventional lipid-lowering therapy.
7. Interaction between Albuminuria and Treatment Group Outcomes for Patients with Renal Artery Stenosis: The NITER Study.
J Vasc Interv Radiol 2018;29:7. PMID: 29843995 , doi: 10.1016/j.jvir.2018.03.003, Cited by. Cite
Conclusion: for similar populations because of inadequate sample size, but, in this sample, patients treated with stent placement who had low albuminuria had better outcomes than patients treated with medical therapy alone.
8. Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension: One-Year Results From the ROX CONTROL HTN Trial.
Hypertension 2017;70:6. PMID: 29061728 , doi: 10.1161/HYPERTENSIONAHA.117.10142, Cited by. Cite
Conclusion: These findings confirm the importance of arterial mechanics in the pathophysiology of hypertension and support the clinical use of a central iliac arteriovenous anastomosis.
Impact/quality: Accompanied by editorial; *
9. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.
Circ Cardiovasc Interv 2017;10:9. PMID: 28916603 , PubMed Central, doi: 10.1161/CIRCINTERVENTIONS.117.005487, Cited by. Cite
Conclusion: Adjunctive elamipretide during PTRA was associated with attenuated postprocedural hypoxia, increased RBF, and improved kidney function in this pilot trial. These data support a role for targeted mitochondrial protection to minimize procedure-associated ischemic injury and to improve outcomes of revascularization for human atherosclerotic renal artery stenosis.
Impact/quality: Accompanied by editorial; * Governmental/foundation support *
10. A randomized, multi-center, prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with hemodynamically relevant atherosclerotic renal artery stenosis (RADAR) - one-year results of a pre-maturely terminated study.
Trials 2017;18:1. PMID: 28807045 , PubMed Central, doi: 10.1186/s13063-017-2126-x, Cited by. Cite
Conclusion: l artery stenting were similar to BMT. These results have to be interpreted with the caveat that the study did not reach its statistically based sample size.
11. Early Removal of Double-J Stents Decreases Urinary Tract Infections in Living Donor Renal Transplantation: A Prospective, Randomized Clinical Trial.
Transplant Proc 2017;49:2. PMID: 28219588 , doi: 10.1016/j.transproceed.2016.12.007, Cited by. Cite
Conclusion: The results of our study demonstrate that ureteral stent removal at 1 week reduces the risk of UTIs compared with routine removal at 4 weeks. Similar effects of ureteral stent removal on complication rates are observed for these two removal times.
12. Relationship of Albuminuria and Renal Artery Stent Outcomes: Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions).
Hypertension 2016;68:5. PMID: 27647847 , PubMed Central, doi: 10.1161/HYPERTENSIONAHA.116.07744, Cited by. Cite
Conclusion: Further research is needed to confirm these preliminary observations.
Impact/quality: Accompanied by editorial; * Governmental/foundation support *
13. Effect of renal artery revascularization upon cardiac structure and function in atherosclerotic renal artery stenosis: cardiac magnetic resonance sub-study of the ASTRAL trial.
Nephrol Dial Transplant 2017;32:6. PMID: 27257278 , doi: 10.1093/ndt/gfw107, Cited by. Cite
Conclusion: In this sub-study of the ASTRAL trial, renal revascularization did not offer additional benefit to cardiac structure or function in unselected patients with ARVD.
Impact/quality: Governmental/foundation support *
14. Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial.
Clin J Am Soc Nephrol 2016;11:7. PMID: 27225988 , PubMed Central, doi: 10.2215/CJN.10491015, Cited by. Cite
Conclusion: eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.
Impact/quality: Accompanied by editorial; * Governmental/foundation support *
15. Renal Artery Stent Outcomes: Effect of Baseline Blood Pressure, Stenosis Severity, and Translesion Pressure Gradient.
J Am Coll Cardiol 2015;66:22. PMID: 26653621 , PubMed Central, doi: 10.1016/j.jacc.2015.09.073, Cited by. Cite
Conclusion: Based on data from the CORAL randomized trial, there is no evidence of a significant treatment effect of the renal artery stent procedure compared with medical therapy alone based on stenosis severity, level of systolic blood pressure elevation, or according to the magnitude of the trans-stenotic pressure gradient. (Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions [CORAL]; NCT00081731).
Impact/quality: Accompanied by editorial; * Governmental/foundation support *
16. Five-year outcomes of staged percutaneous coronary intervention in the SYNTAX study.
EuroIntervention 2015;10:12. PMID: 25912390 , doi: 10.4244/EIJV10I12A244, Cited by. Cite
Conclusion: There is a higher incidence of MACCE in patients undergoing staged compared to single-session PCI for 3-vessel and/or left main disease over the first five years of follow-up. However, these patients had more comorbidities and more diffuse disease.
17. Is fibromuscular dysplasia underdiagnosed? A comparison of the prevalence of FMD seen in CORAL trial participants versus a single institution population of renal donor candidates.
Vasc Med 2014;19:5. PMID: 25082538 , doi: 10.1177/1358863X14544715, Cited by. Cite
Conclusion: The odds of FMD in the CORAL cohort were 2.65 times that seen in the renal donor cohort (95% CI: 1.12, 7.57). In C: onclusion, the 5.8% prevalence of renal artery FMD in the CORAL trial population, the presence of which was biased against, suggests underdiagnosis.
Impact/quality: Governmental/foundation support *
18. Use of renin-angiotensin inhibitors in people with renal artery stenosis.
Clin J Am Soc Nephrol 2014;9:7. PMID: 24903387 , PubMed Central, doi: 10.2215/CJN.11611113, Cited by. Cite
Conclusion: Kidney function and diabetes were associated with renin-angiotensin inhibitor use. However, these or other clinical characteristics did not explain variability among study sites. Patients with renal artery stenosis who received renin-angiotensin inhibitor treatment had lower BP and were more likely to be at treatment goal.
Impact/quality: Accompanied by editorial; * Governmental/foundation support *
19. Roll-in experience from the Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study.
J Vasc Interv Radiol 2014;25:4. PMID: 24325931 , PubMed Central, doi: 10.1016/j.jvir.2013.09.018, Cited by. Cite
Conclusion: In the roll-in phase of the CORAL study, a significant number of angiographic complications were identified. No effect was seen on estimated glomerular filtration rate after renal artery stent placement, but systolic blood pressure decreased significantly.
Impact/quality: Accompanied by editorial; * Governmental/foundation support *
20. Stenting and medical therapy for atherosclerotic renal-artery stenosis.
N Engl J Med 2014;370:1. PMID: 24245566 , PubMed Central, doi: 10.1056/NEJMoa1310753, Cited by. Cite
Conclusion: Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease. (Funded by the National Heart, Lung and Blood Institute and others; ClinicalTrials.gov number, NCT00081731.).
Impact/quality: Accompanied by editorial; * Governmental/foundation support *
21. Renal artery stenosis in patients with resistant hypertension.
Am J Cardiol 2013;112:9. PMID: 24135303 , doi: 10.1016/j.amjcard.2013.06.030, Cited by. Cite
Conclusion: In patients with MBG >22 mm Hg, SBP decreased by 12 versus 3 mm Hg (p <0.01) in patients with MBG ≤22 mm Hg, whereas diastolic blood pressure in both groups decreased by 3 versus 1 mm Hg, respectively (NS). In conclusion, MBG value of >22 mm Hg provides the highest accuracy in predicting hypertension improvement after stenting for moderate RAS in patients with resistant hypertension.
22. EuroSCORE II versus additive and logistic EuroSCORE in patients undergoing percutaneous coronary intervention.
Am J Cardiol 2013;112:3. PMID: 23642508 , doi: 10.1016/j.amjcard.2013.03.032, Cited by. Cite
Conclusion: The Brier score displayed similar global accuracy between the ESII and logES. In conclusion, the ESII is better calibrated than the logES at 30 days but does not represent a step forward in discrimination and global accuracy compared with its previous versions for predicting early- and long-term mortality of patients undergoing PCI.
23. Adjunctive ultrasonography to minimize iodinated contrast administration during carotid artery stenting: a randomized trial.
J Endovasc Ther 2012;19:5. PMID: 23046330 , doi: 10.1583/JEVT-12-3918R.1, Cited by. Cite
Conclusion: Ultrasonography-assisted CAS is feasible and safe. Its use can significantly lower the usage of iodinated contrast and the number of selective cerebral circulation injections while not prolonging the length of the procedure or the fluoroscopy time.
24. Cardiac events in hypertensive patients with renal artery stenosis treated with renal angioplasty or drug therapy: meta-analysis of randomized trials.
Am J Hypertens 2012;25:11. PMID: 22854636 , doi: 10.1038/ajh.2012.110, Cited by. Cite
Conclusion: In patients with ARAS and hypertension, there is a lack of evidence supporting the superiority of PTRA over medical therapy in prevention of nonfatal myocardial infarction. Awaiting for results of ongoing trials, our data and previous data suggest that PTRA and drug therapy have a similar impact on cardiovascular risk reduction in patients with renal artery stenosis and hypertension.
25. Effect of renal artery stenting on left ventricular mass: a randomized clinical trial.
Am J Kidney Dis 2012;60:1. PMID: 22495466 , doi: 10.1053/j.ajkd.2012.01.022, Cited by. Cite
Conclusion: Our study was unable to detect a clinically significant benefit of renal revascularization on LVMI in patients with coronary artery disease and renal artery stenosis of 50%-80%.
26. In high risk hypertensive subjects with incidental and unilateral renal artery stenosis percutaneous revascularization with stent improves blood pressure control but not glomerular filtration rate.
Minerva Cardioangiol 2011;59:6. PMID: 22134468 , Cited by. Cite
Conclusion: PR-STENT reduces systolic BP without improving GFR. Due to the strong association between high BP and renal damage, this study raises the question on whether PR-STENT should be performed in all HTs with unilateral and incidental RAS.
27. Sirolimus- vs. paclitaxel-eluting stent to coronary intervention in dialysis patients.
Int J Cardiol 2013;165:3. PMID: 22000423 , doi: 10.1016/j.ijcard.2011.09.078, Cited by. Cite
Conclusion: There was no significant difference in angiographical outcome at 8-month follow-up between HD patients treated with SES and PES. Even if treated with DES including SES and PES, patients on HD are at high risk of restenosis after PCI.
28. Determinants of renal function in patients with renal artery stenosis.
Vasc Med 2011;16:5. PMID: 21908683 , doi: 10.1177/1358863X11419998, Cited by. Cite
Conclusion: Clinical Trial Registration - URL:http://www.clinicaltrials.gov. Unique identifier: NCT00234585.
Impact/quality: Governmental/foundation support *
29. The Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS) study: rationale and study design.
J Hum Hypertens 2012;26:8. PMID: 21716318 , doi: 10.1038/jhh.2011.62, Cited by. Cite
Conclusion: Patients will be randomized to either arms considering both resistance index value in the ischemic kidney and the presence of unilateral/bilateral stenosis. Primary experimental endpoint will be the GFR of the ischemic kidney, assessed as quantitative variable by 99TcDTPA, and the loss of ischemic kidney defined as a categorical variable.
30. The importance of expert feedback during endovascular simulator training.
J Vasc Surg 2011;54:1. PMID: 21636241 , doi: 10.1016/j.jvs.2011.01.058, Cited by. Cite
Conclusion: VR simulator training for novices can significantly improve general performance in the absence of expert trainers. Procedure-specific qualitative metrics are improved with expert feedback, but nonexpert facilitators can also enhance the quality of training and may represent a valuable alternative to expert clinical faculty.
31. Renal ischemia regulates marinobufagenin release in humans.
Hypertension 2010;56:5. PMID: 20823380 , PubMed Central, doi: 10.1161/HYPERTENSIONAHA.110.155564, Cited by. Cite
Conclusion: In conclusion, we have found that marinobufagenin levels are increased in patients with RAS, whereas reversal of renal ischemia by stenting treatment reduces marinobufagenin levels. These results suggest that RAS-induced renal ischemia may be a major cause of marinobufagenin release.
Impact/quality: Governmental/foundation support *
32. Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy.
Catheter Cardiovasc Interv 2010;76:1. PMID: 20209644 , doi: 10.1002/ccd.22469, Cited by. Cite
Conclusion: Capture of DE and specifically platelet DE are common during protected renal stenting using a filter-type EPD. Abciximab use, and potentially combined thienopyridine and abciximab use, decreased the rate of platelet rich DE; however, only abciximab improved renal function at 1-month.
Impact/quality: Accompanied by editorial; *
33. Revascularization versus medical therapy for renal-artery stenosis.
N Engl J Med 2009;361:20. PMID: 19907042 , doi: 10.1056/NEJMoa0905368, Cited by. Cite
Conclusion: We found substantial risks but no evidence of a worthwhile clinical benefit from revascularization in patients with atherosclerotic renovascular disease. (Current Controlled Trials number, ISRCTN59586944.)
Impact/quality: Governmental/foundation support * Review (at http://www.acpjc.org/); **
34. RADAR - A randomised, multi-centre, prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with haemodynamically relevant atherosclerotic renal artery stenosis.
Trials 2009;10:. PMID: 19635148 , PubMed Central, doi: 10.1186/1745-6215-10-60, Cited by. Cite
Conclusion: Approximately 30 centres in Europe and South America will enrol patients. Duration of enrolment is expected to be 12 months resulting in study duration of 48 months.
35. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.
Ann Intern Med 2009;150:12. PMID: 19414832 , doi: 10.7326/0003-4819-150-12-200906160-00119, Cited by. Cite
Conclusion: Stent placement with medical treatment had no clear effect on progression of impaired renal function but led to a small number of significant procedure-related complications. The study findings favor a conservative approach to patients with ARAS, focused on cardiovascular risk factor management and avoiding stenting.
36. Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial.
J Nephrol 2009;22:1. PMID: 19229814 , Cited by. Cite
Conclusion: All randomized patients receive antihypertensive, lipid-lowering or antiplatelet drugs according to current clinical guidelines. The estimated sample size needed to achieve a 80% power to detect as statistically significant a 4 g/m2 difference in left ventricular mass index progression (p<0.01, 2-tailed) between the 2 arms is 168 (84 in the revascularization arm and 84 in the medical management arm).
37. Complete versus partial distal embolic protection during renal artery stenting.
Catheter Cardiovasc Interv 2009;73:6. PMID: 19198007 , doi: 10.1002/ccd.21932, Cited by. Cite
Conclusion: Complete protection was superior to partial protection for the capture of athermanous debris during renal artery stenting. However, this was not associated with improved renal function. Importantly, Abciximab conferred a benefit for renal function that was independent of the degree of embolic protection.
Impact/quality: Accompanied by editorial; *
38. Prospective randomized trial of operative vs interventional treatment for renal artery ostial occlusive disease (RAOOD).
J Vasc Surg 2009;49:3. PMID: 19135837 , doi: 10.1016/j.jvs.2008.10.006, Cited by. Cite
Conclusion: Both treatment modalities showed good early results concerning RVH, kidney function, and renal perfusion. Despite a higher number of bilateral renal artery reconstructions in patients undergoing OSRP, which was probably due to the preferred technique of transaortic endarterectomy eliminating the plaque originating in the aorta and usually extending into both renal arteries, mortality was not higher and procedure-related morbidity was even lower compared to PTRA + stent. These findings and also longer durability of OSRP imply that surgical reconstruction remains the gold standard for patients with RAOOD before PTRA + stent may be considered.
39. Angiographic and intravascular ultrasound assessment of immediate and 9-month efficacy of percutaneous transluminal renal artery balloon angioplasty with subsequent brachytherapy in patients with renovascular hypertension.
Kidney Blood Press Res 2008;31:5. PMID: 18772602 , doi: 10.1159/000153249, Cited by. Cite
Conclusion: IVBT after PTRA with a self-centering source is a safe and effective method for prevention of restenosis in patients with renovascular hypertension.
40. Embolic protection and platelet inhibition during renal artery stenting.
Circulation 2008;117:21. PMID: 18490527 , doi: 10.1161/CIRCULATIONAHA.107.730259, Cited by. Cite
Conclusion: Renal artery stenting alone, stenting with embolic protection, and stenting with abciximab were associated with a decline in glomerular filtration rate. An unanticipated interaction between Angioguard and abciximab was seen, with combination therapy better than no treatment or either treatment alone.
41. Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far.
J Hum Hypertens 2007;21:7. PMID: 17377602 , doi: 10.1038/sj.jhh.1002185, Cited by. Cite
Conclusion: The trial is due to close to recruitment in April 2007, with the first presentation of the results of the randomized treatment comparison planned for the spring of 2008. To date ASTRAL is by far the largest randomized trial in ARVD, and will provide the most reliable and timely evidence on the role, if any, of revascularization in ARVD with which to guide the treatment of future patients.
Impact/quality: Accompanied by editorial; * Governmental/foundation support *
42. Identification of skills common to renal and iliac endovascular procedures performed on a virtual reality simulator.
Eur J Vasc Endovasc Surg 2007;33:5. PMID: 17291792 , doi: 10.1016/j.ejvs.2006.12.022, Cited by. Cite
Conclusion: Novice endovascular surgeons can significantly improve their performance of simulated procedures through repeated practice on VR simulators. Skills transfer between tasks was demonstrated but complex task training, such as selective arterial cannulation in simulators and possibly in the real world appears to involve a separate skill. It is thus suggested that a stepwise and hierarchical training curriculum is developed for acquisition of endovascular skill using VR simulation to supplement training on patients.
Impact/quality: Accompanied by editorial; *
43. Atherosclerotic renovascular disease: medical therapy versus medical therapy plus renal artery stenting in preventing renal failure progression: the rationale and study design of a prospective, multicenter and randomized trial (NITER).
J Nephrol 2005;18:4. PMID: 16245247 , Cited by. Cite
Conclusion: Medical therapy means drugs to control hypertension, improve dyslipidemia and optimize platelet anti-aggregant therapy. The sample size is estimated in 50 patients per group to achieve a statistical significance of 0.05 in case of a reduction by 50% in the combined endpoints.
44. Midterm results of the multicenter trial of the powerlink bifurcated system for endovascular aortic aneurysm repair.
J Vasc Surg 2004;40:5. PMID: 15557896 , doi: 10.1016/j.jvs.2004.08.051, Cited by. Cite
Conclusion: The Powerlink system appears safe, and effectively protects patients from AAA rupture over the intermediate term. The graft and stent materials have thus far been free from failure and fatigue. Percutaneous contralateral limb access facilitates graft placement in patients with disadvantaged access routes. Endovascular aneurysm repair with the Powerlink system produces significantly fewer early adverse events compared with open AAA repair, but mortality is equivalent with both procedures. Careful follow-up over the longer term is necessary to ensure the durability of these results.
45. Renal function and survival after renal artery stent revascularization may be influenced by embolic debris.
J Invasive Cardiol 2004;16:4. PMID: 15152144 , Cited by. Cite
Conclusion: Renal function remained stable following stent revascularization for RAS, and survival was adversely affected by the variables of unilateral or bilateral RAS, presence of one/two kidneys, renal function impairment and medically controlled BP. These data underscored the premise that the malignant nephropathy associated with RAS was more likely to be segmental than uniform, and resulted from recurrent debris embolization from the obstructing lesion rather than persistent ischemia. Thus, a randomized stent revascularization trial utilizing an embolic protection device, coupled with an effort to collect retrospective preoperative SCr values, may be able to demonstrate post-stent functional stabilization, halting of progressive functional deterioration and, potentially, improvement in survival.
Impact/quality: Accompanied by editorial; *
46. The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design.
J Nephrol 2003;16:6. PMID: 14736007 , Cited by. Cite
Conclusion: The primary outcome of this study is a reduction in Cr clearance > 20% compared to baseline. This trial will include 140 patients.
47. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction.
Circulation 2003;108:22. PMID: 14638545 , doi: 10.1161/01.CIR.0000103623.63687.21, Cited by. Cite
Conclusion: Baseline RI in patients with AMI undergoing primary PCI is associated with a markedly increased risk of mortality, as well as bleeding and restenosis. Novel approaches are needed to improve the otherwise poor prognosis of patients with RI and AMI.
48. The kidney transplant program at the Bergamo Center.
Clin Transpl 2000;:. PMID: 11512311 , Cited by. Cite
Conclusion: Moreover, Doppler ultrasound scanning is an useful, reliable, non-invasive tool to monitor the renal function response to artery revascularization. Thanks to the long-lasting co-operation with the Negri Bergamo Laboratories, we had in the past and still have an active program in experimental animals to investigate strategies for transplant tolerance and transplant gene therapy, besides addressing some issues related to the immunological barrier of xenotransplantation.
49. Prospective studies of diagnosis and intervention: the Dutch experience.
Semin Nephrol 2000;20:5. PMID: 11022900 , Cited by. Cite
Conclusion: Apart from the treatment of patients with specific characteristics, the presented therapeutic approach starts with extending the antihypertensive drug therapy to control blood pressure. Only if blood pressure cannot be controlled or if renal function deteriorates, balloon angioplasty (with stent placement) is indicated.
50. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial.
Lancet 1999;353:9149. PMID: 9929021 , doi: 10.1016/S0140-6736(98)04432-8, Cited by. Cite
Conclusion: PTAS is a better technique than PTA to achieve vessel patency in ostial atherosclerotic renal-artery stenosis. Primary PTAS and primary PTA plus PTAS as rescue therapy have similar outcomes. However, the burden of reintervention after PTA outweighs the potential saving in stents, so primary PTAS is a better approach to use.
Show evidence search details (access to earlier iterations If results displayed are too restrictive)
 
 
You found 50 or more articles.
Consider performing your search at Trip Database. Trip curates the articles it indexes so you may get a smaller number of more helpful documents.
Friday, 29 Mar 2024 04:53:53 at SUMSearch
 
Questions: rbadgett@kumc.edu